Compare SFBC & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFBC | PEPG |
|---|---|---|
| Founded | 1953 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.8M | 121.7M |
| IPO Year | 2012 | 2022 |
| Metric | SFBC | PEPG |
|---|---|---|
| Price | $45.30 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.17 |
| AVG Volume (30 Days) | 8.8K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 53.89 | 25.61 |
| EPS | ★ 0.61 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $75.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.68 | $1.01 |
| 52 Week High | $48.85 | $7.80 |
| Indicator | SFBC | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 38.93 |
| Support Level | $43.81 | $1.47 |
| Resistance Level | $44.93 | $1.96 |
| Average True Range (ATR) | 1.57 | 0.22 |
| MACD | -0.24 | -0.07 |
| Stochastic Oscillator | 22.09 | 1.09 |
Sound Financial Bancorp Inc operates as the holding company for Sound Community Bank that provides traditional banking and other financial services for individuals and businesses. It attracts retail and commercial deposits from the public and invests those funds, along with borrowed funds, in loans secured by first and second mortgages on one-to-four-family residences including home equity loans and lines of credit, commercial and multifamily real estate, construction and land, consumer and commercial business loans. The bank also offers secured and unsecured consumer loan products, including manufactured home loans, floating home loans, automobile loans, boat loans, and recreational vehicle loans.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.